Avidity Biosciences Inc (RNA)

$72.75 -0.17 (-0.23%)
Market Cap 11.27B
Revenue (ttm) 10.90M
Net Income (ttm) -322.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,956.88%
Debt to Equity Ratio 0.00
Volume 4,512,920
Avg Vol 2,219,330
Day's Range N/A - N/A
Shares Out 154.74M
Stochastic %K 64%
Beta 0.93
Analysts Sell
Price Target $73.83

Company Profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known as Bryce Therapeutics, Inc. Atrium Therapeutics, Inc. w...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 876 0700
Address:
10578 Science Center Drive, Suite 125, San Diego, United States
StocktwitsEarnings
StocktwitsEarnings Mar. 6 at 7:00 PM
$RNA Q4 '25 Earnings Results & Recap Avidity Biosciences expects research and development expenses to increase for the foreseeable future as it advances clinical programs, and believes existing cash, cash equivalents, and marketable securities will fund operations for at least 12 months from the Form 10-K filing date.
0 · Reply
marionil
marionil Mar. 3 at 6:34 PM
$RNA not yet thought it was coming yesterday or today.
0 · Reply
Tomekat30
Tomekat30 Mar. 3 at 3:52 PM
$RNA
0 · Reply
Ivory_Joe
Ivory_Joe Mar. 2 at 7:41 PM
$RNA Did anybody get their buyout yet? I thought we were getting $72/share?
1 · Reply
Tomekat30
Tomekat30 Mar. 2 at 12:19 PM
$RNA
0 · Reply
DailyAnalysis
DailyAnalysis Mar. 2 at 5:13 AM
$RNA is effectively pinned after the Novartis merger announcement at seventy-two dollars. 1W and 1D indicators like STOCH are static, while 4H and 30M timeframes show low-volatility trading as the stock aligns with the cash offer. @DailyAnalysis
1 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 12:56 PM
$RNA - OUTLOOK Price is approaching trendline resistance. Structure remains compressed under this key level. If we get breakout of the TL, upside is expected. BIAS: Bullish on TL breakout. SUMMARY: Trendline acting as decision point. Clean breakout can trigger upside continuation.
0 · Reply
Mikeneys
Mikeneys Feb. 28 at 10:06 AM
$RNA biotech developments guiding sentiment
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 6:24 AM
$RNA - Breakdown With Momentum Damage Structure: Sharp gap-down from ~18 → 14–15 base. RSI: 8 (extreme oversold). MACD: Heavy negative impulse. Read: Bounce likely, but structure damaged. Levels Resistance: 15.50 → 16.20 Support: 14 → 13 Alpha: Oversold bounce candidate; not a swing long until +16 reclaim.
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 5:49 AM
$RNA The company has completed its merger and notified Nasdaq of its intent to delist its common stock, requesting that Nasdaq file a Form 25 to remove and deregister the shares, with trading to be suspended on March 2, 2026; following the effectiveness of the Form 25, the company plans to file a Form 15 to terminate its SEC registration and reporting obligations, and the business will now operate as Atrium Therapeutics, Inc., trading under the new Nasdaq ticker symbol RNAM.
0 · Reply
Latest News on RNA
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Feb 27, 2026, 9:19 AM EST - 8 days ago

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 26, 2026, 4:02 PM EST - 9 days ago

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Feb 23, 2026, 8:00 AM EST - 12 days ago

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Feb 18, 2026, 5:00 PM EST - 17 days ago

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Announces Expected Record Date for Spin-Off

Feb 2, 2026, 9:44 PM EST - 4 weeks ago

Avidity Biosciences Announces Expected Record Date for Spin-Off

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 5 weeks ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GKOS GMAB

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

Jan 28, 2026, 4:15 PM EST - 5 weeks ago

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

SNOA

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 7 weeks ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

AZN GEHC LLY

Top 2 Health Care Stocks That May Keep You Up At Night In December

Dec 16, 2025, 8:30 AM EST - 2 months ago

Top 2 Health Care Stocks That May Keep You Up At Night In December

HSIC

These 15 stocks are still showing momentum — and a market-beating edge

Nov 20, 2025, 3:45 PM EST - 3 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 19, 2025, 9:13 AM EST - 3 months ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 10, 2025, 4:05 PM EST - 4 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 4 months ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 8:05 PM EDT - 4 months ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Oct 27, 2025, 2:52 PM EDT - 4 months ago

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

NVS

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 12:31 PM EDT - 4 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 10:22 AM EDT - 4 months ago

Is it too late to buy Avidity stock after Novartis deal?

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

Oct 27, 2025, 8:16 AM EDT - 4 months ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

Oct 27, 2025, 6:54 AM EDT - 4 months ago

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

HSBC NVS

Novartis shares slip, Avidity soars after $12 billion biotech deal

Oct 27, 2025, 6:29 AM EDT - 4 months ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 4 months ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

Oct 26, 2025, 5:33 PM EDT - 4 months ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 4 months ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 4 months ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 4 months ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Oct 26, 2025, 1:07 PM EDT - 4 months ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Oct 26, 2025, 1:00 PM EDT - 4 months ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Oct 26, 2025, 12:26 PM EDT - 4 months ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

Oct 26, 2025, 11:09 AM EDT - 4 months ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 16, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 13, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 15, 2025, 4:01 PM EDT - 6 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 7:56 PM EDT - 6 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Sep 11, 2025, 2:36 PM EDT - 6 months ago

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sep 11, 2025, 8:08 AM EDT - 6 months ago

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LOVE VERI

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Sep 10, 2025, 5:40 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 4:01 PM EDT - 6 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:45 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 10:15 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:37 AM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 6 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Novartis weighs deal for biotech Avidity Biosciences, FT reports

Aug 6, 2025, 11:41 AM EDT - 7 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 28, 2025, 9:00 AM EDT - 7 months ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

StocktwitsEarnings
StocktwitsEarnings Mar. 6 at 7:00 PM
$RNA Q4 '25 Earnings Results & Recap Avidity Biosciences expects research and development expenses to increase for the foreseeable future as it advances clinical programs, and believes existing cash, cash equivalents, and marketable securities will fund operations for at least 12 months from the Form 10-K filing date.
0 · Reply
marionil
marionil Mar. 3 at 6:34 PM
$RNA not yet thought it was coming yesterday or today.
0 · Reply
Tomekat30
Tomekat30 Mar. 3 at 3:52 PM
$RNA
0 · Reply
Ivory_Joe
Ivory_Joe Mar. 2 at 7:41 PM
$RNA Did anybody get their buyout yet? I thought we were getting $72/share?
1 · Reply
Tomekat30
Tomekat30 Mar. 2 at 12:19 PM
$RNA
0 · Reply
DailyAnalysis
DailyAnalysis Mar. 2 at 5:13 AM
$RNA is effectively pinned after the Novartis merger announcement at seventy-two dollars. 1W and 1D indicators like STOCH are static, while 4H and 30M timeframes show low-volatility trading as the stock aligns with the cash offer. @DailyAnalysis
1 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 12:56 PM
$RNA - OUTLOOK Price is approaching trendline resistance. Structure remains compressed under this key level. If we get breakout of the TL, upside is expected. BIAS: Bullish on TL breakout. SUMMARY: Trendline acting as decision point. Clean breakout can trigger upside continuation.
0 · Reply
Mikeneys
Mikeneys Feb. 28 at 10:06 AM
$RNA biotech developments guiding sentiment
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 6:24 AM
$RNA - Breakdown With Momentum Damage Structure: Sharp gap-down from ~18 → 14–15 base. RSI: 8 (extreme oversold). MACD: Heavy negative impulse. Read: Bounce likely, but structure damaged. Levels Resistance: 15.50 → 16.20 Support: 14 → 13 Alpha: Oversold bounce candidate; not a swing long until +16 reclaim.
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 28 at 5:49 AM
$RNA The company has completed its merger and notified Nasdaq of its intent to delist its common stock, requesting that Nasdaq file a Form 25 to remove and deregister the shares, with trading to be suspended on March 2, 2026; following the effectiveness of the Form 25, the company plans to file a Form 15 to terminate its SEC registration and reporting obligations, and the business will now operate as Atrium Therapeutics, Inc., trading under the new Nasdaq ticker symbol RNAM.
0 · Reply
IntraTrades
IntraTrades Feb. 28 at 12:35 AM
$RNA Perhaps.
0 · Reply
UgoGreg
UgoGreg Feb. 27 at 11:18 PM
$RNA https://youtu.be/b4CDDEB3OQo
0 · Reply
Vandelay_Industries_Inc
Vandelay_Industries_Inc Feb. 27 at 9:36 PM
$RNA Really like spinoffs and this one has all the hallmarks. Started buying small here and will look to accumulate if the opportunity arises over the next couple of weeks.
0 · Reply
Laurapicksright
Laurapicksright Feb. 27 at 7:29 PM
$TPET oil sector squeezing this might be the time Oil goes parabolic war is coming and the whole market is signaling this loaded with a starter here same setup as $RNA $KORE $ONMD $BATL
0 · Reply
Tomekat30
Tomekat30 Feb. 27 at 6:41 PM
$RNA my gambling is paying off.
0 · Reply
dgbio
dgbio Feb. 27 at 6:19 PM
$RNA This is not Avidity anymore. Welcome to Atrium
0 · Reply
UgoGreg
UgoGreg Feb. 27 at 5:14 PM
$RNA https://youtu.be/rA5Hfb6n7xQ
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 27 at 4:40 PM
$RNA is effectively pinned after the Novartis merger announcement at seventy-two dollars. 1W and 1D indicators like STOCH are static, while 4H and 30M timeframes show low-volatility trading as the stock aligns with the cash offer. @DailyAnalysis
0 · Reply
Tomekat30
Tomekat30 Feb. 27 at 4:00 PM
$RNA loaded more at $13. Always a gamble
1 · Reply
RonIsWrong
RonIsWrong Feb. 27 at 3:41 PM
$RNA Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
0 · Reply
ChuckSeagal
ChuckSeagal Feb. 27 at 3:37 PM
$LBGJ $ALBT $RNA Welcome to the US Stock Market!
0 · Reply
SippinPurp
SippinPurp Feb. 27 at 3:19 PM
$RNA https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy
0 · Reply